Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial

Size: px
Start display at page:

Download "Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial"

Transcription

1 European Heart Journal (2003) 24, ARTICLE IN PRESS Clinical research Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial Gavin J. Blake b *, Michelle A. Albert b, Nader Rifai a, Paul M. Ridker b a Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA b Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA Received 24 March 2003; received in revised form 17 July 2003; accepted 31 July 2003 KEYWORDS LDL particle concentration; Lipoproteins; Statin Aim Recent data suggests that LDL particle concentration, as determined by Nuclear Magnetic Resonance (NMR) spectroscopy, may be associated with cardiovascular risk. We sought to determine the effect of randomization to pravastatin therapy on LDL particle concentration-nmr, among a primary prevention population. Methods and results LDL particle concentration-nmr, LDL size-nmr, and standard chemical lipid parameters were measured at baseline and after 12 weeks among 500 individuals without overt coronary disease randomly allocated to pravastatin 40 mg (n=256) or placebo (n=244). Randomization to pravastatin therapy caused a 19% reduction in median LDL particle concentration-nmr at 12 weeks, as compared to a 4.2% increase among those randomized to placebo (P<0.001 for pravastatin group compared to placebo). Pravastatin therapy caused a median 24.9% reduction in LDL cholesterol measured chemically compared to a 0.9% increase in the placebo group (P<0.001). Pravastatin therapy did not cause a significant change in median LDL size-nmr (0.5% increase in pravastatin group vs 0.0% in placebo group; P=0.25). The change in LDL particle concentration with pravastatin correlated inversely with baseline LDL size (r= 0.24; P<0.001) such that the largest reduction in LDL particle concentration-nmr was among those with the smallest LDL size-nmr at baseline (median% change =21.4% for tertile 1 of LDL size, 19.9% for tertile 2, and 16.5% for tertile 3; P=0.03). In contrast, pravastatin-induced changes in LDL cholesterol did not correlate with baseline LDL size-nmr (r= 0.05; P=0.47). Conclusion Among individuals without overt hyperlipidemia or known coronary artery disease, randomized allocation to pravastatin (40 mg) therapy for 12 weeks caused a reduction in LDL particle concentration-nmr, the magnitude of which was dependent on baseline LDL size-nmr Published by Elsevier Ltd on behalf of The European Society of Cardiology. Introduction * Corresponding author: Dr Gavin Blake, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston MA , USA. Tel.: ; fax: address: gblake@partners.org (G.J. Blake). Nuclear Magnetic Resonance (NMR) spectroscopy provides a means for the quantification of low-density lipoprotein (LDL) particle concentration and size. Recent data suggests that LDL particle concentration-nmr may be associated with future cardiovascular risk. 1,2 However, little is known about the effect of risk factor modification on LDL particle concentration-nmr and whether this lipoprotein parameter differs from traditional lipid measures. While certain statins have been reported to lower LDL particle concentration-nmr among patients X/03/$ - see front matter 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology. doi: /j.ehj

2 1844 G.J. Blake et al. with dyslipidemia, 3 6 data regarding the effect of HMG- CoA reductase inhibition on this lipoprotein risk factor among individuals without hyperlipidemia or known coronary disease are sparse. We sought to determine the effect of pravastatin on LDL particle concentration- NMR and size-nmr in a substudy of the Pravastatin Inflammation/CRP Evaluation (PRINCE) study, 7 a randomized trial of pravastatin therapy versus placebo. Methods As described elsewhere, 7,8 PRINCE was a community-based, prospective, randomized trial of pravastatin 40 mg/day versus placebo carried out among 2882 men and women aged 21 years or older, who were free of statin use during the 6-month period prior to enrollment, and had no contraindications to statin therapy. Participants had known baseline LDL-Cholesterol levels of at least 130 mg/dl. 7,8 The current NMR based sub-study was conducted among a random selection of 500 participants in the PRINCE trial who had no prior history of cardiovascular disease, 256 of whom were randomized to pravastatin and 244 of whom were randomized to placebo. Blood samples obtained at baseline and 12 weeks were stored in liquid nitrogen until analysis. Total cholesterol, LDL cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride levels were measured in a Centers for Disease Control and Prevention-standardized laboratory. Lipoprotein subclass profiles were measured by proton NMR spectroscopy (LipoScience Inc., Raleigh, NC) as previously described In brief, the NMR method uses the characteristic signals broadcast by lipoprotein subclasses of different size as the basis of their quantification. Each subclass signal emanates from the aggregate number of terminal methyl groups on the lipids contained within the particle. Cholesterol esters and triglycerides in the particle core each contribute three methyl groups and phospholipids and unesterified cholesterol in the surface shell each contribute two methyl groups. To a close approximation, the diameter of the particle determines the number of methyl groups present (and hence, the amplitude of the methyl NMR signal), irrespective of differences in lipid composition arising from, for example, variations in the relative amounts of cholesterol ester and triglyceride in the particle core, varying degrees of unsaturation of the lipid fatty acyl chains, or varying phospholipid composition. For this reason, the methyl NMR signal emitted by each subclass serves as a direct measure of the concentration of that subclass. NMR spectra of each plasma specimen were acquired in duplicate at 47 o C on an automated 400 MHz lipoprotein analyzer and the lipid methyl signal envelope decomposed computationally to give the amplitudes of the contributing signals of 16 lipoprotein subclasses, among which are 4 LDL subclasses (IDL: 25±2 nm; large LDL: 22±0.7 nm; intermediate LDL: 20.5±0.7 nm; and small LDL: 19±0.7 nm). To obtain the conversion factors needed to relate these LDL signal amplitudes to particle concentrations, purified subclass standards were obtained and subjected to chemical lipid and NMR analysis. The subclass standards were isolated from a diverse group of normo- and dyslipidemic individuals by a combination of ultracentrifugation and agarose gel chromatography and characterized for size distribution by electron microscopy. Particle concentrations (nanomoles of particles per liter, nmol/l) were derived for each subclass standard by measuring the total core lipid concentration (cholesterol ester plus triglyceride) and dividing the volume occupied by these lipids by the calculated core volume per particle. 12 Reported LDL particle concentrations (NMR) are the sums of the concentrations of the LDL subclasses (including IDL). For all biochemical and NMR analyses, samples were handled in a fully blinded fashion such that all investigators had no knowledge of randomization status. Weighted average LDL particle sizes were computed as the sum of the diameter of each LDL subclass (excluding IDL) multiplied by its relative mass percentage as estimated from the amplitude of its methyl NMR signal. NMR LDL sizes are closely related to those estimated by gradient gel electrophoresis, but are uniformly smaller by approximately 5 nm, because they are referenced differently to diameters assessed by electron microscopy. With 90% power and a significance level of 0.05, a sample size of 190 per group was required to detect a 10% change in LDL particle concentration with pravastatin therapy compared to placebo. We randomly selected 500 participants in the PRINCE trial who had no prior history of cardiovascular disease. Of these 500 randomly selected participants, 256 were in the pravastatin group, and 244 in the placebo group. Baseline characteristics among the group randomized to pravastatin and the group randomized to placebo were compared with the chi squared test for categorical variables, and student s t-test or Wilcoxon rank sum test for continuous variables. The median change and the median percent change in NMR measurements and lipid levels observed over the 12 week time course were also computed, and the significance of differences was evaluated between randomized treatment groups with the Wilcoxon rank sum test. Spearman correlation coefficients were computed to assess the association between on-treatment change in NMR parameters and lipid parameters. In order to further assess whether the change in LDL particle concentration-nmr observed with pravastatin was dependent upon baseline levels of LDL size-nmr, the group randomized to pravastatin were divided into tertiles according to baseline LDL size-nmr and the differences between the observed change in LDL particle concentration-nmr in these three groups was assessed by the Kruskal Wallace test. All P-values were two sided and a P value <0.05 was considered statistically significant. Results The baseline clinical characteristics of the study population, according to randomized assignment to placeo and pravastatin, are shown in Table of the study population were randomized to receive placebo and 256 to pravastatin therapy. There was a higher proportion of current smokers in the placebo group. Otherwise, the treatment groups did not differ with respect to age, gender, body mass index, diabetes, medication use, or lipid parameters. Baseline median levels of LDL particle concentration-nmr ( nmol/l [interquartile range ] vs nmol/l [ ], P=0.93) and LDL size-nmr (20.8 nm [ ] vs 20.8 nm [ ], P=0.82) were similar among those randomized to placebo and those randomized to pravastatin. As shown in Table 2, randomization to pravastatin therapy caused a 19.0% reduction in median LDL particle concentration-nmr compared to a 4.2% increase in the placebo group (P<0.001). This compared with a median 24.9% reduction in chemically measured LDL cholesterol with pravastatin therapy compared to a 0.9% increase in

3 Pravastatin and LDL particle concentration 1845 Table 1 the placebo group (P<0.001). Pravastatin therapy did not cause a significant change in median LDL size-nmr compared to placebo (0.5% increase in pravastatin group compared to 0.0% in placebo group at 12 weeks, P=0.25). As expected, pravastatin therapy reduced levels of total cholesterol (median% change = 18.3%; P<0.001 compared to placebo), and triglycerides (median % change = 16.4%; P<0.001 compared to placebo), while causing a smaller increase in HDL levels (median % change=+5.5%; P=0.002 compared to placebo). Among those randomized to pravastatin therapy, the change in LDL particle concentration-nmr correlated significantly with the change in LDL cholesterol (r=0.58, P<0.001) and total cholesterol (r=0.58, P<0.001) and correlated inversely with the change in HDL-cholesterol (r= 0.14, P=0.03). The change in LDL particle concentration-nmr with pravastatin therapy did not differ significantly among current smokers and non-smokers (17.7% [ %] vs 19.1% [ %]; P=0.92). Finally the change in LDL particle concentration-nmr with pravastatin therapy correlated inversely with baseline LDL size (r= 0.24; P<0.001). To further explore this relationship, we conducted further analyses whereby those randomized to pravastatin were divided into tertiles according to baseline LDL size-nmr. As shown in Table 3, pravastatin therapy caused the largest reduction in LDL particle concentration-nmr among those with the smallest LDL size-nmr at baseline (median % change=21.4% for tertile 1, 19.9% for tertile 2, and 16.5% for tertile 3; P=0.03). In contrast the pravastatin-induced change in LDL cholesterol did not correlate with baseline LDL size (r= 0.05; P=0.47). Discussion Baseline characteristics of study population In this substudy of a randomized placebo controlled trial, we found that randomization to pravastatin therapy for Placebo (n=244) a Pravastatin (n=256) a P value Age (years) 57.3± ± Male 60.3% 58.9% 0.76 Body mass index (kg/m 2 ) 28.9± ± Smoking Never 45.1% 51.7% Ex 32.4% 36.4% Current 22.5% 11.9% Diabetes 9.8% 10.7% 0.76 Current aspirin use 24.5% 29.6% 0.20 Current HRT use 19.3% 20.2% 0.82 Total cholesterol (mg/dl) ± ± LDL-C (mg/dl) ± ± HDL-C (mg/dl) 39.46± ± Triglycerides (mg/dl) [ ] [ ] 0.64 LDL particle concentration (nmol/l) [ ] [ ] 0.93 LDL size (nm) 20.8 [ ] 20.8 [ ] 0.82 HRT=hormone replacement therapy; LDL-C=low-density lipoprotein cholesterol; HDL-C=high-density lipoprotein cholesterol. a Values are mean±sd or median [interquartile range]. 12 weeks resulted in a 19% reduction in LDL particle concentration-nmr. This compared with a 24.9% reduction in LDL cholesterol with pravastatin therapy. Median LDL size-nmr did not change significantly with pravastatin therapy, but the reduction in LDL particle concentration-nmr with pravastatin therapy was most marked among those with smallest LDL size-nmr at baseline. In contrast the change in LDL cholesterol with pravastatin therapy was not related to baseline LDL size-nmr. Apolipoprotein B-100 has been used as an estimate of LDL particle concentration and has been shown previously to correlate strongly with LDL particle concentration-nmr. 1 In this regard, the observed reductions in LDL particle concentration-nmr with pravastatin therapy in this study are consistent with previous reports of reductions in apolipoprotein B-100 with statin therapy ranging from 13 25% among selected subpopulations A previous report of the effect of pravastatin therapy on LDL particle concentration-nmr reported a 24% change in LDL particle concentration-nmr after 6 months of mg of pravastatin among patients with documented coronary artery disease. 5 Larger reductions in LDL particle concentration-nmr have been reported with atorvastatin therapy among 101 patients with atherogenic dyslipidemia 3 and simvastatin therapy among 20 patients with mixed hyperlipidemia. 4 That our data found somewhat smaller reductions may reflect that statins of different potency vary in their effects on LDL particle concentration, but also may reflect that our population was free of known cardiovascular disease and had lower baseline LDL particle concentrations. We observed no change in median LDL size-nmr after 12 weeks of pravastatin therapy. This finding is consistent with the majority of other studies of the effect of statin therapy on LDL size assessed by other

4 Table 2 Changes in LDL particle concentration-nmr, LDL size-nmr, and lipid parameters according to randomized assignment to pravastatin or placebo Placebo Pravastatin P value Baseline 12 weeks Median % change Baseline 12 weeks Median% change (Pravastatin vs placebo) NMR measures LDL particle concentration (nmol/l) % % <0.001 small LDL (nmol/l) a intermediate LDL (nmol/l) <0.001 a large LDL (nmol/l) a IDL (nmol/l) a LDL size (nm) % % 0.25 Chemical lipid measures Total cholesterol (mg/dl) % % <0.001 LDL-cholesterol (mg/dl) % % <0.001 HDL-cholesterol (mg/dl) % % Triglycerides (mg/dl) % % <0.001 Values are medians, except for total cholesterol, LDL-cholesterol, and HDL-cholesterol where values are mean. LDL=low-density lipoprotein; HDL=high-density lipoprotein. a P values for the LDL subgroups refer to median absolute changes in LDL subgroup concentration in the pravastatin group compared to the placebo group G.J. Blake et al. Downloaded from at Pennsylvania State University on March 6, 2014

5 Pravastatin and LDL particle concentration 1847 Table 3 Effect of baseline tertile of LDL size-nmr on changes in LDL particle concentration-nmr with pravastatin therapy. Baseline LDL size LDL particle concentration Tertile 1 (<20.6 nm) a Tertile 2 ( nm) a Tertile 3 (>20.9 nm) a P value Baseline (nmol/l) [ ] [ ] [ ] 12 week (nmol/l) [ ] [ ] [ ] Median absolute change [137.0±557.5] [ ] [ ] Median % change 21.4% [ %] 19.9% [ %] 16.5% [ %] 0.03 LDL=low-density lipoprotein. a All values are median [interquartile range]. techniques, 14,17 19 although a recent study using NMR spectroscopy observed a small (1.5%) increase in LDL size with atorvastatin therapy among patients with hypertriglyceridemia. 3 The magnitude of change in LDL particle concentration-nmr with pravastatin therapy did appear dependent on baseline LDL size-nmr with the greatest reduction observed among those with the smallest LDL size-nmr. This finding is also consistent with recent data from the Pravastatin Limitation of Atherosclerosis in the Coronaries-1 (PLAC-1) trial. 5 This study has a number of limitations. The proportion of current smokers was higher among those randomized to placebo than among those randomized to pravastatin. However, the effect of pravastatin on LDL particle concentration-nmr was similar among smokers and nonsmokers, and thus we believe this chance occurrence is unlikely to have affected our results. We did not measure apolipoprotein B-100 levels in the PRINCE study. Finally, the use of frozen samples could theoretically have affected our results. Nonetheless, the observed levels of LDL particle concentration-nmr and size-nmr and lipid values are consistent with those reported in other studies. 1,2,5,20 In sum, randomized allocation to 40 mg of pravastatin therapy for 12 weeks caused a 19% reduction in LDL particle concentration-nmr among 500 patients without overt hyperlipidemia or known coronary artery disease. The magnitude of reduction in LDL particle concentration-nmr with pravastatin therapy was dependent on baseline LDL size-nmr. This association with LDL size was not observed for on treatment changes in LDL cholesterol. Further work is required to confirm the effect of other preventive dietary and pharmacological interventions on LDL particle concentration-nmr. References 1. Blake GJ, Otvos JD, Rifai N et al. LDL particle concentration and size as determined by NMR spectroscopy as predictors of cardiovascular events in women. Circulation 2002;106: Kuller L, Arnold A, Tracy R et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 2002; 22: McKenney JM, McCormick LS, Schaefer EJ et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 2001;88: Miller M, Dolinar C, Cromwell W et al. Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia. Am J Cardiol 2001;87: Otvos JD, Shalaurova I, Freedman DS et al. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis 2002;160: Schaefer EJ, McNamara JR, Tayler T et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol 2002;90: Albert MA, Danielson E, Rifai N et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/crp evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286: Albert MA, Staggers J, Chew P et al. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J 2001; 141: Otvos JD, Jeyarajah EJ, Bennett DW. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin Chem 1991;37: Otvos JD, Jeyarajah EJ, Bennett DW et al. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992;38: Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 2002;48: Redgrave TG, Carlson LA. Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridemic man. J Lipid Res 1979;20: Bredie SJ, de Bruin TW, Demacker PN et al. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-b-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 1995;75: Cheung MC, Austin MA, Moulin P et al. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis 1993;102: Zambon S, Cortella A, Sartore G et al. Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size. Eur J Clin Pharmacol 1994;46: Rubenfire M, Maciejko JJ, Blevins RD et al. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. The Southeastern Michigan Collaborative Group. Arch Intern Med 1991;151: Superko HR, Krauss RM, DiRicco C. Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am J Cardiol 1997;80: Kontopoulos AG, Athyros VG, Papageorgiou AA et al. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis 1996;7: Franceschini G, Cassinotti M, Vecchio G et al. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb 1994;14: Freedman DS, Otvos JD, Jeyarajah EJ et al. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998;18:

The Framingham Coronary Heart Disease Risk Score

The Framingham Coronary Heart Disease Risk Score Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although

More information

LIPOPROTEIN PROFILING

LIPOPROTEIN PROFILING LIPOPROTEIN PROFILING in CLINICAL DIAGNOSTICS and LIFE SCIENCE RESEARCH Product Information, March 2015 2004-2015, numares HEALTH LIPOPROTEINS AND CARDIOVASCULAR DISEASE High blood cholesterol is a well-known

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition

More information

The apolipoprotein story

The apolipoprotein story Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical

More information

Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome

Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome A randomized, double-blind,

More information

Relationship of Apolipoprotein B Levels to the Number of Risk Factors for Metabolic Syndrome

Relationship of Apolipoprotein B Levels to the Number of Risk Factors for Metabolic Syndrome ORIGINAL INVESTIGATION Relationship of Apolipoprotein B Levels to the Number of Risk Factors for Metabolic Syndrome Jacob J. Clarenbach, Scott M. Grundy, Natalia Palacio, and Gloria Lena Vega Low-density

More information

CARDIO Test INFAI. for Cardiac Risk Assessment

CARDIO Test INFAI. for Cardiac Risk Assessment CARDIO Test INFAI for Cardiac Risk Assessment Heart Attack and Stroke: A Worldwide Problem NMR analysis of serum to assess the risk of cardiovascular disease Headquarter in Cologne (RTZ) Facility in Bochum

More information

Low-density lipoprotein (LDL) comprises a heterogeneous

Low-density lipoprotein (LDL) comprises a heterogeneous Fluvastatin Lowers Atherogenic Dense Low-Density Lipoproteins in Postmenopausal Women With the Atherogenic Lipoprotein Phenotype Winfried März, MD; Hubert Scharnagl, BSc; Claudia Abletshauser, MD; Michael

More information

What Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives

What Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives 9: 1:am Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis SPEAKER Matthew Sorrentino, MD, FACC Presenter Disclosure Information The following relationships exist

More information

Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI

Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI Biochemical Analysis (Lipid Panel) Analyte Total Cholesterol Reference Range Patient A < 200 241 LDL-C /= 40 38 Triglycerides

More information

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain

More information

Effects of Niacin on LDL Particle Number

Effects of Niacin on LDL Particle Number www.medscape.com Effects of Niacin on LDL Particle Number Haseeb Jafri, Richard H Karas, Jeffrey T Kuvin Clin Lipidology. 2009;4(5):565-571. Abstract and Niacin Overview Abstract Niacin has long been used

More information

Lipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease

Lipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease Lipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease Policy Number: Original Effective Date: MM.02.013 02/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO;

More information

Moderate alcohol consumption is associated with decreased

Moderate alcohol consumption is associated with decreased Alcohol Consumption and Plasma Concentration of C-Reactive Protein Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Moderate alcohol intake has been associated with

More information

Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol

Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol Patrick R. Lawler, MD, MPH; Akintunde O. Akinkuolie, MBBS,

More information

sad EFFECTIVE DATE: POLICY LAST UPDATED:

sad EFFECTIVE DATE: POLICY LAST UPDATED: Medical Coverage Policy Measurement of Small Low Density Lipoprotein Particles sad EFFECTIVE DATE: 02 16 2010 POLICY LAST UPDATED: 10 15 2013 OVERVIEW Lipoprotein-associated phospholipase A2 (Lp-PLA2),

More information

Effects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease.

Effects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease. Michael Garshick, MD PGY-1 Columbia University Medical Center Effects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease. Study Purpose and Rationale:

More information

ARTICLE. Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients

ARTICLE. Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients ARTICLE Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients Baruch S. Ticho, MD, PhD; Ellis J. Neufeld, MD, PhD; Jane W. Newburger, MD, MPH; Neil Harris,

More information

Measurement of Trigly ceride-rich Lipoproteins by Nuclear Magnetic Resonance Spectroscopy

Measurement of Trigly ceride-rich Lipoproteins by Nuclear Magnetic Resonance Spectroscopy Clin. Cardiol. Vol. 22 (Suppl. 11), 11-21-11-27 (1999) Measurement of Trigly ceride-rich Lipoproteins by Nuclear Magnetic Resonance Spectroscopy JAMES CII'VOS, PH.D. Department of Biochemistry, North Carolina

More information

William Campbell Cromwell, MD Curriculum Vitae

William Campbell Cromwell, MD Curriculum Vitae William Cromwell, MD Medical Director Division of Lipoprotein Disorders Presbyterian Center for Preventive Cardiology Presbyterian Cardiovascular Institute Adjunct Associate Professor Wake Forest University

More information

Metabolism and Atherogenic Properties of LDL

Metabolism and Atherogenic Properties of LDL Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal

More information

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,

More information

ATP IV: Predicting Guideline Updates

ATP IV: Predicting Guideline Updates Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations

More information

Approach to Dyslipidemia among diabetic patients

Approach to Dyslipidemia among diabetic patients Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences

More information

Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date

Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date MP 2.04.13 Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with

More information

Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women

Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women Diabetes Publish Ahead of Print, published online February 25, 2010 Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women Samia Mora, MD, MHS,

More information

Best Lipid Treatments

Best Lipid Treatments Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

Zuhier Awan, MD, PhD, FRCPC

Zuhier Awan, MD, PhD, FRCPC Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier

More information

Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals

Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia

More information

N-3 Fatty Acids Non-HDL-Cand LDL-C Thomas Dayspring MD, FACP

N-3 Fatty Acids Non-HDL-Cand LDL-C Thomas Dayspring MD, FACP Omega or N-3 Fatty Acids (FA) significantly reduce TG synthesis and significantly deplete the TG content of VLDL particles indicated by significantly reduced V. FA are the substrate for TG synthesis. N3-FA

More information

Coverage Guidelines. NMR LipoProfile and NMR LipoProfile -II Tests

Coverage Guidelines. NMR LipoProfile and NMR LipoProfile -II Tests Coverage Guidelines NMR LipoProfile and NMR LipoProfile -II Tests Disclaimer: Please note that Baptist Health Plan updates Coverage Guidelines throughout the year. A printed version may not be most up

More information

Katsuyuki Nakajima, PhD. Member of JCCLS International Committee

Katsuyuki Nakajima, PhD. Member of JCCLS International Committee Katsuyuki Nakajima, PhD Member of JCCLS International Committee Visiting Professor and Scientist Tufts University, Boston, MA & Framingham Offspring Study, Framingham, MA August 20 th, 2011, Tokyo Framingham

More information

NIH Public Access Author Manuscript Atherosclerosis. Author manuscript; available in PMC 2010 December 1.

NIH Public Access Author Manuscript Atherosclerosis. Author manuscript; available in PMC 2010 December 1. NIH Public Access Author Manuscript Published in final edited form as: Atherosclerosis. 2009 December ; 207(2): 524. doi:10.1016/j.atherosclerosis.2009.05.001. Lipoprotein Particle Subclasses, Cardiovascular

More information

Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date

Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date MP 2.04.22 Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

NIH Public Access Author Manuscript J Clin Lipidol. Author manuscript; available in PMC 2009 August 4.

NIH Public Access Author Manuscript J Clin Lipidol. Author manuscript; available in PMC 2009 August 4. NIH Public Access Author Manuscript Published in final edited form as: J Clin Lipidol. 2007 December 1; 1(6): 583 592. doi:10.1016/j.jacl.2007.10.001. LDL Particle Number and Risk of Future Cardiovascular

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:

More information

Hyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi

Hyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia

More information

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry

More information

Comparison of Effects of High (80 mg) Versus Low (20 mg) Dose of Simvastatin

Comparison of Effects of High (80 mg) Versus Low (20 mg) Dose of Simvastatin Comparison of Effects of High (80 mg) Versus Low (20 mg) Dose of Simvastatin on C-Reactive Protein and Lipoproteins in Patients With Angiographic Evidence of Coronary Arterial Narrowing Kent G. Meredith,

More information

Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin-Resistant Diabetes

Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin-Resistant Diabetes Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin-Resistant Diabetes 2 Michael Cobble, Patrick D. Mize, and Eliot A. Brinton Insulin Resistance and Type 2 Diabetes The pathophysiology of

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease. Original Policy Date

High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease. Original Policy Date MP 2.04.17 High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date

More information

Measurement of Small Dense Low-density Lipoprotein Particles

Measurement of Small Dense Low-density Lipoprotein Particles 67 Journal of Atherosclerosis and Thrombosis Reviews Vol. 12, No. 2 Measurement of Small Dense Low-density Lipoprotein Particles Tsutomu Hirano 1, Yasuki Ito 2, and Gen Yoshino 3 1 Division of Diabetes

More information

Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures

Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers William Cromwell, MD, FAHA, FNLA Diplomate, American Board of Clinical Lipidology Chief Lipoprotein and Metabolic

More information

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing

More information

Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia

Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia ISPUB.COM The Internet Journal of Cardiovascular Research Volume 3 Number 1 Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia V Save, N Patil, G Rajadhyaksha Citation V Save,

More information

REAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING

REAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND

More information

The insulin resistance syndrome (IRS) is a trait

The insulin resistance syndrome (IRS) is a trait Effects of Insulin Resistance and Type 2 Diabetes on Lipoprotein Subclass Particle Size and Concentration Determined by Nuclear Magnetic Resonance W. Timothy Garvey, 1,2 Soonho Kwon, 1 Deyi Zheng, 3 Sara

More information

Hypertriglyceridemia, Inflammation, & Pregnancy

Hypertriglyceridemia, Inflammation, & Pregnancy Hypertriglyceridemia, Inflammation, & Pregnancy Richard L. Nemiroff, MD, FACOG, NLA Professor, Clinical Gynecology Perelman School of Medicine University of Pennsylvania Philadelphia, PA Disclosure of

More information

Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp

Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp Página 1 de 5 Return to Medscape coverage of: American Society of Hypertension 21st Annual Scientific Meeting and Exposition Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions

More information

Lipoprotein Particle Profile

Lipoprotein Particle Profile Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular

More information

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:

More information

B. Patient has not reached the percentage reduction goal with statin therapy

B. Patient has not reached the percentage reduction goal with statin therapy Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels

More information

Hae Sun Suh, B.Pharm., Ph.D. Jason N. Doctor, Ph.D.

Hae Sun Suh, B.Pharm., Ph.D. Jason N. Doctor, Ph.D. Podium Presentation, May 18, 2009 Comparison of Cardiovascular Event Rates in Subjects with Type II Diabetes Mellitus who Augmented from Statin Monotherapy to Statin Plus Fibrate Combination Therapy with

More information

Achieving Secondary Prevention Low-Density Lipoprotein Particle Concentration Goals Using Lipoprotein Cholesterol-Based Data

Achieving Secondary Prevention Low-Density Lipoprotein Particle Concentration Goals Using Lipoprotein Cholesterol-Based Data Achieving Secondary Prevention Low-Density Lipoprotein Particle Concentration Goals Using Lipoprotein Cholesterol-Based Data Simon C. Mathews 1, Jaya Mallidi 2,3, Krishnaji Kulkarni 4, Peter P. Toth 5,

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

Projected Life-Expectancy Gains With Statin Therapy for Individuals With Elevated C-Reactive Protein Levels

Projected Life-Expectancy Gains With Statin Therapy for Individuals With Elevated C-Reactive Protein Levels Journal of the American College of Cardiology Vol. 40, No. 1, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01914-9

More information

Lipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures

Lipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures Lipoprotein (a): Should We Measure? Should We Treat? Joseph P. McConnell, Ph.D. DABCC Health Diagnostic Laboratory Inc. Baptist Health South Florida Eleventh Annual Cardiovascular Disease Prevention International

More information

2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:

2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug: 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:

More information

STATIN UTILIZATION MANAGEMENT CRITERIA

STATIN UTILIZATION MANAGEMENT CRITERIA STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,

More information

Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size

Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size Atherosclerosis 180 (2005) 127 135 Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size Paolo M. Suter a,, Gabrielle Marmier a, Caroline Veya-Linder b, Edgar

More information

LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV

LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 4 (53) No. 2-2011 LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV C. DOBRESCU 1 I. MOLEAVIN 1 Abstract:

More information

Journal of the American College of Cardiology Vol. 48, No. 9, by the American College of Cardiology Foundation ISSN /06/$32.

Journal of the American College of Cardiology Vol. 48, No. 9, by the American College of Cardiology Foundation ISSN /06/$32. Journal of the American College of Cardiology Vol. 48, No. 9, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.06.067

More information

Management of Post-transplant hyperlipidemia

Management of Post-transplant hyperlipidemia Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and

More information

Epidemiologic evidence has long suggested that

Epidemiologic evidence has long suggested that 182 PREVENTIVE CARDIOLOGY FALL 2004 REVIEW PAPER CME The Effects of Niacin on Lipoprotein Subclass Distribution John M. Morgan, MD; Christina M. Carey, PA-C; Anne Lincoff, MD; David M. Capuzzi, MD, PhD

More information

Lipoprotein Subpopulation Distributions in Lean, Obese, and Type 2 Diabetic Women: A Comparison of African and White Americans

Lipoprotein Subpopulation Distributions in Lean, Obese, and Type 2 Diabetic Women: A Comparison of African and White Americans Lipoprotein Subpopulation Distributions in Lean, Obese, and Type 2 Diabetic Women: A Comparison of African and White Americans Paul S. MacLean, Joseph F. Bower, Satyaprasad Vadlamudi, Thomas Green, and

More information

Pharmacologic Characteristics of Statins

Pharmacologic Characteristics of Statins Clin. Cardiol. Vol. 26 (Suppl. III), III-32 III-38 (2003) Pharmacologic Characteristics of Statins JAMES M. MCKENNEY, PHARM.D. National Clinical Research, Inc., and School of Pharmacy, Virginia Commonwealth

More information

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,

More information

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical

More information

Changing lipid-lowering guidelines: whom to treat and how low to go

Changing lipid-lowering guidelines: whom to treat and how low to go European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,

More information

PREDIABETES TESTING SERVICES

PREDIABETES TESTING SERVICES PREDIABETES TESTING SERVICES ASSESSING DIABETES RISK IN ASYMPTOMATIC ADULTS Depending upon population characteristics, up to 70% of individuals with prediabetes will ultimately progress to diabetes at

More information

Fasting or non fasting?

Fasting or non fasting? Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues

More information

Nearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III

Nearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated

More information

C-Reactive Protein Levels and Outcomes after Statin Therapy

C-Reactive Protein Levels and Outcomes after Statin Therapy The new england journal of medicine original article C-Reactive Protein Levels and Outcomes after Statin Therapy Paul M Ridker, M.D., Christopher P. Cannon, M.D., David Morrow, M.D., Nader Rifai, Ph.D.,

More information

Journal of the American College of Cardiology Vol. 36, No. 1, by the American College of Cardiology ISSN /00/$20.

Journal of the American College of Cardiology Vol. 36, No. 1, by the American College of Cardiology ISSN /00/$20. Journal of the American College of Cardiology Vol. 36, No. 1, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00680-X Lack

More information

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,

More information

Weintraub, W et al NEJM March Khot, UN et al, JAMA 2003

Weintraub, W et al NEJM March Khot, UN et al, JAMA 2003 Global risk hscrp Should not be included in a Global Cardiovascular Risk Assessment. Jodi Tinkel, MD Assistant Professor Director of Cardiac Rehabilitation Associate Program Director, Cardiovascular Medicine

More information

The CARI Guidelines Caring for Australians with Renal Impairment. Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy

The CARI Guidelines Caring for Australians with Renal Impairment. Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All hypercholesterolaemic diabetics

More information

Chapter (5) Etiology of Low HDL- Cholesterol

Chapter (5) Etiology of Low HDL- Cholesterol Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the

More information

Jose L. Barboza Jr, Pharm.D. Candidate INSIDE THIS ISSUE: UPDATE ON STATINS: FOCUS ON UNAPPROVED USES. Table 1. Currently Marketed Statins

Jose L. Barboza Jr, Pharm.D. Candidate INSIDE THIS ISSUE: UPDATE ON STATINS: FOCUS ON UNAPPROVED USES. Table 1. Currently Marketed Statins Jose L. Barboza Jr, Pharm.D. Candidate O ver two decades ago, the first HMG-CoA reductase inhibitor (statin) was approved to treat hypercholesterolemia, a major modifiable risk factor for cardiovascular

More information

High density lipoprotein metabolism

High density lipoprotein metabolism High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC

More information

journal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract

journal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract The new england journal of medicine established in 1812 november 20, 2008 vol. 359 no. 21 to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M Ridker, M.D., Eleanor Danielson,

More information

Type 1 diabetes is associated with an increased

Type 1 diabetes is associated with an increased Lipoprotein Subclasses and Particle Sizes and Their Relationship With Coronary Artery Calcification in Men and Women With and Without Type 1 Diabetes Helen M. Colhoun, 1 James D. Otvos, 2 Mike B. Rubens,

More information

New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines

New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular

More information

Antihyperlipidemic drugs

Antihyperlipidemic drugs Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual

More information

Rapid Effects of Simvastatin on Lipid Profile and C-Reactive Protein in Patients with Hypercholesterolemia

Rapid Effects of Simvastatin on Lipid Profile and C-Reactive Protein in Patients with Hypercholesterolemia Clin. Cardiol. 26, 472 476 (2003) Rapid Effects of Simvastatin on Lipid Profile and C-Reactive Protein in Patients with Hypercholesterolemia JIAN-JUN LI, M.D., PH.D., MING-ZHE CHEN, M.D., XIN CHEN, M.D.,

More information

Welcome! Mark May 14, Sat!

Welcome! Mark May 14, Sat! Welcome! Mark May 14, Sat! Do We Have All Answers with Statins In Treating Patients with Hyperlipidemia? Kwang Kon Koh, MD, PhD, FACC, FAHA Cardiology, Gil Heart Center, Gachon Medical School, Incheon,

More information

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society

More information

C-REACTIVE PROTEIN AND LDL CHOLESTEROL FOR PREDICTING CARDIOVASCULAR EVENTS

C-REACTIVE PROTEIN AND LDL CHOLESTEROL FOR PREDICTING CARDIOVASCULAR EVENTS COMPARISON OF C-REACTIVE PROTEIN AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN THE PREDICTION OF FIRST CARDIOVASCULAR EVENTS PAUL M. RIDKER, M.D., NADER RIFAI, PH.D., LYNDA ROSE, M.S., JULIE E. BURING,

More information

LDL How Low can (should) you Go and be Safe

LDL How Low can (should) you Go and be Safe LDL How Low can (should) you Go and be Safe Edward Shahady MD, FAAFP, ABCL Clinical Professor Family Medicine Medical Director Diabetes Master Clinician Program Definition of Low LDL National Health and

More information

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins - Cholesterol: It is a sterol which is found in all eukaryotic cells and contains an oxygen (as a hydroxyl group OH) on Carbon number

More information

A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease.

A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease. A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease. Brian A. Ference MD, MPhil, MSc, John J. P. Kastelein

More information

MOLINA HEALTHCARE OF CALIFORNIA

MOLINA HEALTHCARE OF CALIFORNIA MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel

More information

Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients

Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract

More information

Acritical component of lowering the cardiovascular disease

Acritical component of lowering the cardiovascular disease Review Systematic Review: Association of Low-Density Lipoprotein Subfractions With Cardiovascular Outcomes Stanley Ip, MD; Alice H. Lichtenstein, ScD; Mei Chung, MPH; Joseph Lau, MD; and Ethan M. Balk,

More information

Ischemic heart disease is the leading cause of

Ischemic heart disease is the leading cause of The impact of C-Reactive Protein: A Look at the Most Recent Studies and Trials By Davinder S. Jassal, MD, FRCPC; and Blair O Neill, MD, FRCPC, FACC Ischemic heart disease is the world s leading killer,

More information